Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ten Programs To Watch Out For At ASCO

Executive Summary

The ASCO abstracts are out – and with them a scramble to see exactly what will be hitting the headlines in early June. Here, with the help of Sagient's BioMedTracker, Scrip takes a look at some of the more interesting studies due to be presented in Chicago in a couple weeks.

Advertisement

Related Content

CASTOR Propels J&J's Anti-CD38 Darzalex To Prime Position In Myeloma
Celator Shines At ASCO, Highlights Upside For Jazz
Immuno-Oncology's Next Wave: Key Targets And Emerging Players
Novartis Oncology Strategy: Focus On The Microenvironment
ASCO Puts A Spotlight On CDK4/6 Category Ahead Of New Competition
Early Tecentriq OK Gives Roche/Genentech Jump On PD-L1 Bladder Cancer Market
Novartis Ups Pace On Ibrance Challenger As Ribociclib Trial Stopped Early
AbbVie Gains Lung Cancer ADC, Solid Tumor Platform With Stemcentrx Buyout
Celator Claims Phase III Vyxeos Victory In AML
Janssen/Genmab Win 1st Anti-CD38 In Multiple Myeloma

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC065245

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel